Qyuns Therapeutics Co Ltd
02509
Company Profile
Business description
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
Contact
No. 907 Yaocheng Avenue
Room 1310, Building 1
Taizhou
Jiangsu
CHNT: +86 52380276311
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
337
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
stocks
Poor organic growth obscured by acquisition for ASX listed share
Sales dropped by 2% without impact of acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.20 | 15.00 | -0.17% |
| CAC 40 | 8,144.53 | 58.53 | 0.72% |
| DAX 40 | 24,864.81 | 258.04 | 1.05% |
| Dow JONES (US) | 50,285.66 | 276.31 | 0.55% |
| FTSE 100 | 10,476.08 | 32.61 | 0.31% |
| HKSE | 25,606.03 | 219.51 | 0.86% |
| NASDAQ | 26,293.10 | 22.74 | 0.09% |
| Nikkei 225 | 63,339.07 | 1,654.93 | 2.68% |
| NZX 50 Index | 12,991.31 | 113.24 | 0.88% |
| S&P 500 | 7,445.72 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,657.00 | 15.10 | -0.17% |
| SSE Composite Index | 4,112.90 | 35.62 | 0.87% |